Sutton, A. J., Edmunds, W. John and Gill, O. N.. (2006) Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison. BMC Public Health, Vol. 6 (No. 17). ISSN 1471-2458

Preview

PDF WRAP_Sutton_Estimating_cost_effectiveness.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (591Kb)

Abstract

Background In England and Wales where less than 1% of the population are Injecting drug users (IDUs), 97% of HCV reports are attributed to injecting drug use. As over 60% of the IDU population will have been imprisoned by the age of 30 years, prison may provide a good location in which to offer HCV screening and treatment. The aim of this work is to examine the cost effectiveness of a number of alternative HCV case-finding strategies on prison reception Methods A decision analysis model embedded in a model of the flow of IDUs through prison was used to estimate the cost effectiveness of a number of alternative case-finding strategies. The model estimates the average cost of identifying a new case of HCV from the perspective of the health care provider and how these estimates may evolve over time. Results The results suggest that administering verbal screening for a past positive HCV test and for ever having engaged in illicit drug use prior to the administering of ELISA and PCR tests can have a significant impact on the cost effectiveness of HCV case-finding strategies on prison reception; the discounted cost in 2017 being £2,102 per new HCV case detected compared to £3,107 when no verbal screening is employed. Conclusion The work here demonstrates the importance of targeting those individuals that have ever engaged in illicit drug use for HCV testing in prisons, these individuals can then be targeted for future intervention measures such as treatment or monitored to prevent future transmission.

Item Type:	Journal Article
Subjects:	H Social Sciences > HN Social history and conditions. Social problems. Social reform
Divisions:	Faculty of Science > Life Sciences (2010- ) > Biological Sciences ( -2010)
Library of Congress Subject Headings (LCSH):	Hepatitis C -- Great Britain, Prisoners -- Medical care, Drug addicts -- Great Britain
Journal or Publication Title:	BMC Public Health
Publisher:	BioMed Central Ltd.
ISSN:	1471-2458
Date:	27 June 2006
Volume:	Vol. 6
Number:	No. 17
Identification Number:	10.1186/1471-2458-6-170
Status:	Peer Reviewed
Access rights to Published version:	Open Access
References:	1. Limburg W: Natural history, treatment and prevention of hepatitis C in injecting drug users; an overview. In Hepatitis C and injecting drug use: impact, costs and policy options Edited by: Jager J, Limburg W, Kretzschmar M, Postma M and Wiessing L. Lisbon, European Monitoring Centre for Drugs and Drug Addiction; 2004:21-38. 2. www.hpa.org.uk. Website 2006. 3. Leal P, Stein K, Rosenberg W: What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users? J Med Screen 1999, 6:124-131. 4. Agency HP, Scotland HP, National Public Health Service for Wales, Ireland CDSCN, CRDHB, UASSG: Shooting Up; Infections among injecting drug users in the United Kingdom 2004, An update: October 2005 London, Health Protection Agency; 2005. 5. Weissing L, Roy K, Sapinho D, Hay G, Taylor A, Goldberg D, Hartnoll R: Surveillance of hepatitis C infection among injecting drug users in the European Union. In Hepatitis C and injecting drug use: impact, costs and policy options Edited by: Jager J, Limburg W, Kretzschmar M, Postma M and Wiessing L. Luxembourg, European Monitoring Centre for Drugs and Drug Addiction; 2006:91-135. 6. Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L: Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect 2002, 129:577-585. 7. de Angelis D, Hickman M, Yang S: Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: back-calculation methods and opiate overdose deaths. Am J Epidemiol 2004, 160:994-1004. 8. Frischer M, Hickman M, Kraus L, Mariani F, Wiessing L: A comparison of different methods for estimating the prevalence of problematic drug misuse in Great Britain. Addiction 2001, 96:1465-1476. 9. Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM: Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut 2003, 52:1500-1504. 10. Schlicting EG, Johnson ME, Brems C, Wells RS, Fisher DG, Reynolds G: Validity of injecting drug users' self report of hepatitis A, B, and C. Clin Lab Sci 2003, 16:99-106. 11. Reuter P: What drug policies cost: estimating government drug policy expenditures. Addiction 2006, 101:315-322. 12. Sutton AJ, Gay NJ, Edmunds WJ, Andrews NJ, Hope VD, Gilbert RL, Piper M, Gill ON: Modelling the hepatitis B vaccination programme in prisons. Epidemiol Infect 2006, 134:231-242. 13. Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M: Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis 2006, 6:93. 14. Macalino GE, Hou JC, Kumar MS, Taylor LE, Sumantera IG, Rich JD: Hepatitis C infection and incarcerated populations. The International Journal of Drug Policy 2004, 151:103-114. 15. Health Protection Agency Centre for Infections: Hepatitis C in England: The First Health Protection Agency Annual Report. London; 2005. 16. Best D, Noble A, Finch E, Gossop M, Sidwell C, Strang J: Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment. BMJ 1999, 319:290-291. 17. Darke S: Self-report among injecting drug users: a review. Drug Alcohol Depend 1998, 51:253-263. 18. Treasury HM: The Green Book, Apprasial and Evaluation in Central Government 2003. 19. Mortimer P: Ready, steady, go for HCV antigen testing? Commun Dis Public Health 2000, 3:154-155. 20. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998, 47:1-39. 21. Horne JA, Clements AJ, Drennan P, Stein K, Cramp ME: Screening for hepatitis C virus in the Dartmoor prison population: an observational study. J Public Health (Oxf) 2004, 26:372-375. 22. Guidance on the use of Ribavirin and Interferon Alpha for Hepatitis C. Volume 14. National Institute for Clinical Excellence; 2000. 23. Curtis L, Netten A: Unit Costs of Health and Social Care Personal Social Services Research Unit; 2004. 24. Stein K, Dalziel K, Walker A, McIntyre L, Jenkins B, Horne J, Royle P, Round A: Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. Health Technol Assess 2002, 6(31):1-122. 25. www.hpa.org.uk. Website 2005. 26. Seeff LB: Natural history of chronic hepatitis C. Hepatology 2002, 36:S35-S46.
URI:	http://wrap.warwick.ac.uk/id/eprint/555

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item